Cell Biology of Parkin: Clues to the Development of New Therapeutics for Parkinson’s Disease Jaimin PatelNikhil PanickerTed M. Dawson Leading Article 15 November 2022 Pages: 1249 - 1267
Comparative Effectiveness of Device-Aided Therapies on Quality of Life and Off-Time in Advanced Parkinson’s Disease: A Systematic Review and Bayesian Network Meta-analysis Angelo AntoniniRajesh PahwaK. Ray Chaudhuri Systematic Review Open access 21 November 2022 Pages: 1269 - 1283
High-Efficacy Therapies for Treatment-Naïve Individuals with Relapsing–Remitting Multiple Sclerosis Léorah FreemanErin E. LongbrakeTimothy Vollmer Review Article Open access 09 November 2022 Pages: 1285 - 1299
A Multicenter, Randomized, Double-Blind, Positive-Controlled, Non-Inferiority, Phase III Clinical Trial Evaluating the Efficacy and Safety of Emulsified Isoflurane for Anesthesia Induction in Patients Hui YangYuJun ZhangWenSheng Zhang Original Research Article 16 November 2022 Pages: 1301 - 1311
Thromboembolic Risks with Concurrent Direct Oral Anticoagulants and Antiseizure Medications: A Population-Based Analysis Bonaventure Y. IpHo KoThomas W. Leung Original Research Article Open access 24 November 2022 Pages: 1313 - 1324
Evaluation of a Rapid Topiramate Titration Scheme for the Early Detection of Cognitive Side Effects Juri-Alexander WittGuido WidmanChristoph Helmstaedter Original Research Article Open access 02 November 2022 Pages: 1325 - 1330
Comment on: “A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Viloxazine Extended-Release Capsules in Adults with Attention Deficit/Hyperactivity Disorder” Alok SinghMahesh Kumar Balasundaram Letter to the Editor 04 November 2022 Pages: 1331 - 1332
Authors’ Reply to Singh and Balasundaram: Comment on “A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Viloxazine Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity Disorder” Azmi NasserJoseph T. HullAnn Childress Letter to the Editor Open access 04 November 2022 Pages: 1333 - 1335
